If MSB is to return to $10..., page-8

Travelightor

I simply point out that you are drawing conclusions without being proportionate about what you are missing out. You mention not having that information, but then assume it is at zero. That's not logical as it doesn't take into account information that is available.

You don't need me to point you in the direction of the fact that CHF in the current application alone will reduce patient hospitalisation, that's a HUGE cost. So the remuneration will be proportionate. You look at the size of the market and get back to me on that.

It's a colossal area. Same with disk repair and arthritis.

You pretend that because there aren't specifics we can just pretend the size of the potential revenue can be disregarded.

You're also ignoring that we are going to market early in Japan with CHF, based on the stage 2 clinical trials with a very small local trial. You totally ignore this factor. How do you manage that?

As for the SP, as I've said many times, it's been manipulated. I have said many times that Macbank make misleading reports and shorted it. The Nasdaq listing was at a difficult time in the market and the same thing happened; a broker shorted it and issued misleading reports.

Exactly how am I responsible for this?

Nothing wrong with a broker looking at the fundamentals of the stock and making accurate and not misleading analysis. The fact that others have manipulated the stock should not shock you. It happens elsewhere in the market.

MSB is one of the most shorted stocks on the ASX and even the shorting information is incomplete and unregulated.

So I take any analysts report with a grain of salt but I would trust some to make an accurate assessment of fundamentals. You can't tell us to ignore Lodge Partners without explaining where you have a factual problem with their assessment. So far you haven't.